Basilea Pharmaceutica AG's latest marketcap:
As of 08/19/2025, Basilea Pharmaceutica AG's market capitalization has reached $805.79 M. According to our data, Basilea Pharmaceutica AG is the 11307th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 805.79 M |
| Revenue (ttm) | 258.93 M |
| Net Income (ttm) | 96.34 M |
| Shares Out | 12.27 M |
| EPS (ttm) | 7.23 |
| Forward PE | 12.73 |
| Ex-Dividend Date | 04/11/2013 |
| Earnings Date | 08/19/2025 |
Basilea Pharmaceutica AG's yearly market capitalization.
| Date | Market Cap(₣) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/19/2025 | ₣648.98 M | $805.79 M | 27.28% | 11307 |
| 12/30/2024 | ₣501.21 M | $551.87 M | 18.52% | 12353 |
| 12/29/2023 | ₣422.9 M | $502.29 M | -22.52% | 12957 |
| 12/30/2022 | ₣545.84 M | $590.11 M | 12.62% | 11206 |
| 12/30/2021 | ₣484.67 M | $531.25 M | -15.59% | 12958 |
| 12/30/2020 | ₣574.19 M | $648.55 M | 14.12% | 10191 |
| 12/30/2019 | ₣503.13 M | $519.28 M | 15.74% | 9847 |
| 12/28/2018 | ₣434.71 M | $442.58 M | -51.52% | 9740 |
| 12/29/2017 | ₣896.66 M | $918.98 M | 3.85% | 7505 |
| 12/30/2016 | ₣863.41 M | $846.22 M | -16.97% | 7222 |
Company Profile
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a biopharmaceutical company specializing in the discovery, development, and commercialization of treatments for bacterial and fungal infections. Headquartered in Allschwil, Switzerland, the company was established in 2000.
Key Products & Pipeline
- Cresemba: An intravenous antifungal medication used to treat invasive aspergillosis and mucormycosis.
- Fosmanogepix: Currently in Phase II clinical trials, this antifungal drug targets Candidemia.
- BAL2062: A treatment for invasive mold infections, now in Phase I clinical trials.
- BAL2420: An antibiotic under development for severe Enterobacteriaceae infections.
- Zevtera: An antibiotic approved for pneumonia treatment, with ongoing development for Staphylococcus aureus bacteremia and acute bacterial skin infections.
Basilea Pharmaceutica AG remains committed to advancing innovative therapies to address critical infectious diseases worldwide.
Frequently Asked Questions
-
What is Basilea Pharmaceutica AG's (SWX-BSLN) current market cap?As of 08/19/2025, Basilea Pharmaceutica AG (including the parent company, if applicable) has an estimated market capitalization of $805.79 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Basilea Pharmaceutica AG (SWX-BSLN) rank globally by market cap?Basilea Pharmaceutica AG global market capitalization ranking is approximately 11307 as of 08/19/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.